AI News Sentiment & Analysis
Arrowhead Pharmaceuticals, Inc. (ARWR) — AI News Sentiment & Analysis
9 recent AI analyses of Arrowhead Pharmaceuticals, Inc. (ARWR) stock news and press releases, with sentiment and confidence scoring updated continuously.
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
BullishClinical ResultsInterim topline Phase 1/2a clinical results for ARO-DIMER-PA (Timing: Upcoming medical congress presentations)Sep 15, 2026Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
BullishClinical ResultsPlanned supplemental New Drug Application (sNDA) submission to the U.S. FDA by year-end 2026 utilizing a Priority Review Voucher. (Timing: Before the end of 2026)Aug 30, 2026Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
BullishClinical ResultsCompletion of Phase 3 YOSEMITE study enrollment, leading to future clinical results and potential regulatory approval for zodasiran. (Timing: Study completion anticipated in mid-2027, with regulatory submissions thereafter.)Jul 27, 2026Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
BullishClinical ResultsSuccessful Phase 3 clinical trial results for plozasiran in severe hypertriglyceridemia and planned supplemental New Drug Application (sNDA) filing. (Timing: Presentation of detailed results at ESC Congress on August 30, 2026, with first sNDA filing in the U.S. before the end of 2026.)Jul 22, 2026Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
BullishRegulatory DecisionFormal European Commission marketing authorization for REDEMPLO (plozasiran) in Familial Chylomicronemia Syndrome (FCS), opening a significant new market for the first-in-class drug. (Timing: Initial sales traction and commercialization progress expected within 6-12 months.)Jun 22, 2026Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
BullishClinical ResultsPositive Phase 1/2a clinical trial results for ARO-INHBE, showing meaningful reductions in liver and visceral fat for obesity and MASH. (Timing: Near-term, as further Phase 2 study designs and regulatory engagements are planned.)May 27, 2026Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
BullishClinical ResultsNew positive clinical data for plozasiran supporting its use in patients with renal or hepatic impairment without dose adjustment, and sustained triglyceride lowering in pregnancy. This expands the addressable market and de-risks the product profile. (Timing: Near-term, as the data influences prescribing decisions and future regulatory considerations, with market expansion realized over the next 6-12 months.)May 26, 2026Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
BullishRegulatory DecisionAustralian TGA approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS), expanding global market access for the drug. (Timing: Immediately, with commercialization efforts following soon after.)May 1, 2026Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
BullishRegulatory DecisionPositive opinion from the European CHMP recommending approval of REDEMPLO for Familial Chylomicronemia Syndrome (FCS). (Timing: European Commission decision expected in Q2 2026.)Apr 24, 2026
Want the full picture?
These are AI-read press-release catalysts. Sign up to see complete investment theses, valuation rationales, entry/exit strategies, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Arrowhead Pharmaceuticals, Inc. (ARWR) bullish or bearish right now?
AI Sentiment on ARWR: 9 Bullish.
What was the latest AI analysis for Arrowhead Pharmaceuticals, Inc. (ARWR)?
The latest analysis was published on 9/15/2026 with the headline: "Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia".
How does Bekodia analyze Arrowhead Pharmaceuticals, Inc. (ARWR) stock?
Bekodia uses advanced AI models to process Arrowhead Pharmaceuticals, Inc. (ARWR) press releases and news in real-time, extracting sentiment, confidence scores, and key investment catalysts while filtering out market noise.